To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years.

Rizk, John G; Gupta, Aashish; Lazo, Jose G; Sardar, Partha; Henry, Brandon Michael; Lavie, Carl J; Effron, Mark B

Rizk, John G; Gupta, Aashish; Lazo, Jose G; Sardar, Partha; Henry, Brandon Michael; Lavie, Carl J; Effron, Mark B.

Afiliación

Rizk JG; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland.
Gupta A; John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana.
Lazo JG; UCSF Medical Center, University of California, San Francisco, San Francisco, California.
Sardar P; John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana.
Henry BM; Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Lavie CJ; Disease Prevention and Intervention & Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas.
Effron MB; John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, Louisiana.

Semin Thromb Hemost ; 49(1): 62-72, 2023 Feb.

Article en En | MEDLINE | ID: mdl-35468641

Asunto(s)

COVID-19; Tromboembolia Venosa; Humanos; COVID-19/complicaciones; Tromboembolia Venosa/etiología; Fibrinolíticos/uso terapéutico; Enfermedad Crítica; Anticoagulantes/efectos adversos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboembolia Venosa / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Semin Thromb Hemost Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google